Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial

Perrett, Kirsten P.; Halperin, Scott A.; Nolan, Terry; Pancorbo, Cristina Martínez; Tapiéro, Bruce; Martinón-Torres, Federico; Straňák, Z; Virta, Maarit; Vanderkooi, Otto G; Kosina, Pavel; Pardilla, María Begoña Encinas; Cristóbal, Ignacio; Zuccotti, Gian Vincenzo; Kostanyan, Lusiné; Meyer, Nadia; Ceregido, Maria Angeles; Cheuvart, Brigitte; Kuriyakose, Sherine; Fernández, Manuel Marcos; Zambrano, Miguel Ángel Rodríguez; García, Adrián Martín; Fuente, Juan Eloy Asenjo de la; Marín, Maria Dolores Camacho; Fernández-Miranda, María de la Calle; Espinar, Yolanda Romero; Marchisio, Paola; Manzoni, Paolo; Mesaros, Narcisa

doi:10.1016/j.vaccine.2019.10.105

Cited by 29 publications

(36 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The fact that BCG and MTBVAC vaccination increases the levels of anti-DT, anti-TT, and anti-PT antibodies after a single dose of DTaP may therefore be more meaningful than increasing antibody responses after the third dose. Even if the effect were transient and similar to the protection of the newborn induced through maternal immunization with pertussis vaccines [ 51 ], it might be clinically relevant considering that this age represents the most vulnerable time-frame for the infant and when most of the cases occur.…”

Section: Discussionmentioning

confidence: 99%

BCG vaccination improves DTaP immune responses in mice and is associated with lower pertussis incidence in ecological epidemiological studies

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background The Bacillus Calmette-Guérin (BCG), the only vaccine against tuberculosis (TB) currently in use, has shown beneficial effects against unrelated infections and to enhance immune responses to vaccines. However, there is little evidence regarding the influence of BCG vaccination on pertussis. Methods Here, we studied the ability of BCG to improve the immune responses to diphtheria, tetanus, and acellular (DTaP) or whole-cell pertussis (DTwP) vaccination in a mouse model. We included MTBVAC, an experimental live-attenuated vaccine derived from Mycobacterium tuberculosis , in our studies to explore if it presents similar heterologous immunity as BCG. Furthermore, we explored the potential effect of routine BCG vaccination on pertussis incidence worldwide. Findings We found that both BCG and MTBVAC when administered before DTaP, triggered Th1 immune responses against diphtheria, tetanus, and pertussis in mice. Immunization with DTaP alone failed to trigger a Th1 response, as measured by the production of IFN-γ. Humoral responses against DTaP antigens were also enhanced by previous immunization with BCG or MTBVAC. Furthermore, exploration of human epidemiological data showed that pertussis incidence was 10-fold lower in countries that use DTaP and BCG compared to countries that use only DTaP. Interpretation BCG vaccination may have a beneficial impact on the protection against pertussis conferred by DTaP. Further randomized controlled trials are needed to properly define the impact of BCG on pertussis incidence in a controlled setting. This could be a major finding that would support changes in immunization policies. Funding This work was supported by the Ministry of “Economía y Competitividad”; European Commission H2020 program, “Gobierno de Aragón”; CIBERES; “Fundação Butantan”; Instituto de Salud Carlos III and “Fondo FEDER”.

show abstract

Section: Discussionmentioning

confidence: 99%

BCG vaccination improves DTaP immune responses in mice and is associated with lower pertussis incidence in ecological epidemiological studies

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…The retrieved literature list (9 publications) was cross-compared with a recent systematic literature review on maternal immunization [2] and two additional publications were identified from the reference lists of selected publications. In addition to the literature search, data from two randomized clinical trials conducted by GSK were included which were not published at the time of the search (www.clinicaltrials.gov: NCT02096263 [15][16][17] and NCT02422264 [18]).…”

Section: Methodsmentioning

confidence: 99%

Immune interference (blunting) in the context of maternal immunization with Tdap-containing vaccines: is it a class effect?

Kandeil

Savic

Ceregido

et al. 2020

Expert Review of Vaccines

Self Cite

View full text Add to dashboard Cite

Introduction: Maternal immunization with reduced antigen content tetanus-diphtheria-acellular pertussis (Tdap)-containing vaccines has been recommended to prevent infant pertussis. However, maternal antibodies may interfere with infant responses to routine immunization with diphtheria-tetanus-acellular pertussis (DTaP)containing vaccines, raising concerns of suboptimal protection after infant vaccination. We performed a narrative literature review to assess whether blunting occurs regardless of the manufacturer of maternal and infant vaccines. Because internationally agreed correlates of protection are lacking, the clinical significance of blunting is not yet fully understood. We have reviewed the evidence available to date. Areas Covered: Thirteen studies that evaluated blunting after maternal immunization and infant primary/booster series were identified. Blunting was observed with various combinations of Tdapand DTaP-containing vaccines for maternal and pediatric immunization. Studies assessing the effectiveness of maternal Tdap immunization beyond the primary infant immunization series in England and in the United States suggested no evidence of a clinically relevant blunting effect so far. Expert commentary: This review indicates that the phenomenon of blunting does not depend on the manufacturer/brand of the pertussis-containing vaccines used for immunizing mothers or children. Currently, there is no epidemiological evidence that children whose mothers received Tdap are at increased risk of pertussis after pediatric vaccinations, although longer follow-up is required.

show abstract

“…Altogether, 6 randomized controlled trials were included in our fnal quantitative analysis [26][27][28][29][30][31]. Healthy pregnant women 18-45 years old who were not at known risk of pregnancy-related complications and had a normal singleton pregnancy were included in all these six studies.…”

Section: Study Characteristicsmentioning

confidence: 99%

Safety and Immunogenicity of Pertussis Vaccine Immunization during Pregnancy: A Meta-Analysis of Randomized Clinical Trials

Simayi

Zhu

Jin

2022

Journal of Tropical Medicine

View full text Add to dashboard Cite

The objective of this meta-analysis is to assess the safety and immunogenicity of maternal pertussis vaccination based on randomized clinical trials. PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Internet, and Wan Fang Database were searched from inception up to the 8th of October 2021, using a protocol registered on PROSPERO with no. 42021287717, and a meta-analysis was conducted. We measured pooled geometric mean concentrations (GMCs) for IgG antibodies against pertussis and the incidence of serious adverse events (SAEs). We identified a total of 522 publications, and after a strict screening, we found that 6 RCTs were eligible for our meta-analysis. GMCs were determined with a standardized mean difference (SMD), and the pooled SMD of anti-PT, anti-FHA, and anti-PRN IgG from cord blood were 0.91 (95% CI: 0.58, 1.24), 1.03 (95% CI: (0.70, 1.35)), and 1.55(95% CI: 1.22, 1.88), respectively. The pooled OR of SAEs of women and infants did not show a statistical difference; the pooled ORs were 1.26 (95% CI: 0.78, 2.05); P = 0.35 ) and 0.61 (95% CI: 0.37, 1.01); p = 0.053 ), respectively. Infants of immunized women have significantly higher transplacental antibodies for protection against pertussis disease during the first 2 months of life.

show abstract

Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial

Cited by 29 publications

References 34 publications

BCG vaccination improves DTaP immune responses in mice and is associated with lower pertussis incidence in ecological epidemiological studies

BCG vaccination improves DTaP immune responses in mice and is associated with lower pertussis incidence in ecological epidemiological studies

Immune interference (blunting) in the context of maternal immunization with Tdap-containing vaccines: is it a class effect?

Safety and Immunogenicity of Pertussis Vaccine Immunization during Pregnancy: A Meta-Analysis of Randomized Clinical Trials

Contact Info

Product

Resources

About